| 
July 14, 2014
Guideline Synthesis Guideline Summaries American Academy of Neurology British Association of Dermatologists CancerControl Alberta Infectious Diseases Society of America Royal College of Obstetricians and Gynaecologists | Announcements NGC Spotlight New research reviews added! Visit the AHRQ Evidence Reports page for a listing of reports produced under AHRQ's Evidence-based Practice Program and Effective Health Care Program. Conference News - The Guidelines International Network (G-I-N) Conference 2014, will be held August 20-23 in Melbourne, Australia. This year's theme is "Creation and Innovation: Guidelines in the Digital Age." Register now.
- The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site.
U.S. Food and Drug Administration (FDA) Advisories - June 26, 2014: Lidocaine Viscous: FDA notified health professionals, their provider organizations and caregivers for infants, that prescription oral viscous lidocaine 2% solution should not be used to treat infants and children with teething pain. FDA is requiring a Boxed Warning to be added to the prescribing information (label) to highlight this information. Oral viscous lidocaine solution is not approved to treat teething pain, and use in infants and young children can cause serious harm, including death.
- June 25, 2014: Over-The-Counter Topical Acne Products: FDA is warning that certain over-the-counter (OTC) topical acne products can cause rare but serious and potentially life-threatening allergic reactions or severe irritation. Consumers should stop using their topical acne product and seek emergency medical attention immediately if they experience hypersensitivity reactions such as throat tightness; difficulty breathing; feeling faint; or swelling of the eyes, face, lips, or tongue. Consumers should also stop using the product if they develop hives or itching. The hypersensitivity reactions may occur within minutes to a day or longer after product use. These serious reactions differ from the local skin irritation that may occur at the product application site that are already included in the Drug Facts labels.
NGC's Sister Resources
| This email was sent to iammejtm@gmail.com using GovDelivery, on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 540 Gaither Road · Rockville, MD 20850 · 301-427-1364 | |
No comments:
Post a Comment